Ugeskr Læger 2017;179:V05160327
Osteoporosis treatment can be discontinued based on an individual assessment
In most patients, treatment of osteoporosis is a long-term challenge. Because alendronate and zoledronic acid accumulate in bone with some persistent antifracture efficacy after therapy, it is reasonable to consider a “drug holiday” for low-risk patients. It is recommended that the duration and length of drug holiday should be individualized for each patient. For all other bisphosphonates data are limited. For other antiresorptive and anabolic agents “drug holiday” is not recommended.